Dr. Mark Murray, Arbutus President & Chief Executive Officer, to participate in a fireside chat at Chardan’s Genetic Medicines Conference at 2:45 pm ET today WARMINSTER, Pa. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV)...

WARMINSTER, Pa. , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark J. Murray , Arbutus’ President and Chief Executive Officer, will present at the Chardan Genetic...

WARMINSTER, Pa. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia , Arbutus’ Chief Scientific Officer, will participate in the Hepatitis B Functional

ONPATTRO Approval Triggers Royalty to Arbutus Clinically Validated LNP Technology Now in the Hands of Genevant to Develop RNA-based Products WARMINSTER, Pa. , Aug. 13, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic

WARMINSTER, Pa. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS ), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia , Arbutus’ Chief Scientific Officer, will present a corporate update at the Wedbush

- Phase 1a/1b study of AB-506, a second-generation oral capsid inhibitor, initiated - Phase 1a/1b study of AB-452, a novel and proprietary oral RNA destabilizer, expected to begin in the second half of 2018 - All oral combination Phase 2 study of AB-506 and AB-452 expected to begin by the end of

WARMINSTER, Pa. , July 19, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its second quarter financial results, conference call and webcast for Thursday, August 2,

First Subject Dosed in Phase 1 Study of AB-506, Arbutus’ Second-Generation Capsid Inhibitor All-Oral Combination Study of AB-506 and AB-452 Expected in 2019 HBsAg Reduction Data from ARB-1467 Expected in Q4 Arbutus Spinout Genevant Enters Transformative Partnership with Leading mRNA Therapeutics

VANCOUVER, British Columbia and WARMINSTER, Pa. , June 18, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will present at the first annual Roivant Pipeline Day on July 10, 2018

VANCOUVER, British Columbia and WARMINSTER, Pa. , June 07, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the appointment of David Hastings as Chief Financial Officer, effective June